Access gap blows out to 676 days

The widely touted figure of 466 days between TGA approval and PBS listing has been blown out of the water with new figures revealing patients now wait an average 676 days for the medicines they need.

Amgen's latest Australian Patient Access Gap Tracker reveals that in the 12 months to April, the average delay has grown by 91 days.

The Tracker calculates the average patient access gap (PAG) days for all medicines and population pairings between January 2021 and April 2025.

To see the whole article please log in.

Log in with your member email for full access.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Email

Retype password

Not a member? Sign up here